FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Price, Quote, News and Overview
TSX:FRX - Toronto Stock Exchange - CA31447P1009 - Common Stock - Currency: CAD
FRX.CA Quote, Performance and Key Statistics
TSX:FRX (2/21/2025, 7:00:00 PM)
9.5
+0.63 (+7.1%)
The current stock price of FRX.CA is 9.5 CAD. In the past month the price increased by 10.59%. In the past year, price decreased by -29.32%.
FRX.CA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 188.23M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 185.09M | ||
| TH.CA | THERATECHNOLOGIES INC | N/A | 121.39M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 89.95M | ||
| ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 82.42M | ||
| MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 78.27M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 25.45 | 76.72M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | 48.5 | 65.22M | ||
| MDCX.CA | MEDICUS PHARMA LTD | N/A | 61.74M | ||
| SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 52.45M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 51.96M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 25.50M |
Related stock screener links
About FRX.CA
Company Profile
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Company Info
FENNEC PHARMACEUTICALS INC
PO Box 13628, 68 Tw Alexander Dr
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US
CEO: Rostislav Raykov
Employees: 36
Company Website: https://fennecpharma.com/
Investor Relations: https://investors.fennecpharma.com/
Phone: 19196364530
FENNEC PHARMACEUTICALS INC / FRX.CA FAQ
What is the stock price of FENNEC PHARMACEUTICALS INC today?
The current stock price of FRX.CA is 9.5 CAD. The price increased by 7.1% in the last trading session.
What is the ticker symbol for FENNEC PHARMACEUTICALS INC stock?
The exchange symbol of FENNEC PHARMACEUTICALS INC is FRX and it is listed on the Toronto Stock Exchange exchange.
On which exchange is FRX.CA stock listed?
FRX.CA stock is listed on the Toronto Stock Exchange exchange.
What is the price forecast or stock price prediction for FENNEC PHARMACEUTICALS INC stock?
11 analysts have analysed FRX.CA and the average price target is 20.1 CAD. This implies a price increase of 111.56% is expected in the next year compared to the current price of 9.5. Check the FENNEC PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FENNEC PHARMACEUTICALS INC worth?
FENNEC PHARMACEUTICALS INC (FRX.CA) has a market capitalization of 261.54M CAD. This makes FRX.CA a Micro Cap stock.
How many employees does FENNEC PHARMACEUTICALS INC have?
FENNEC PHARMACEUTICALS INC (FRX.CA) currently has 36 employees.
What are the support and resistance levels for FENNEC PHARMACEUTICALS INC (FRX.CA) stock?
FENNEC PHARMACEUTICALS INC (FRX.CA) has a support level at 9.27 and a resistance level at 9.71. Check the full technical report for a detailed analysis of FRX.CA support and resistance levels.
Is FENNEC PHARMACEUTICALS INC (FRX.CA) expected to grow?
The Revenue of FENNEC PHARMACEUTICALS INC (FRX.CA) is expected to grow by 179.16% in the next year. Check the estimates tab for more information on the FRX.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FENNEC PHARMACEUTICALS INC (FRX.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FRX.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FRX.CA, evaluating the profitability, health, valuation and growth aspects
- FENNEC PHARMACEUTICALS INC (FRX.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FENNEC PHARMACEUTICALS INC (FRX.CA) Sales and EPS estimates to see what analysts future expectations are.
- FENNEC PHARMACEUTICALS INC (FRX.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FENNEC PHARMACEUTICALS INC (FRX.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Chart to make your own analysis
- FENNEC PHARMACEUTICALS INC (FRX.CA) Latest news and press-releases to stay up to date.
Does FENNEC PHARMACEUTICALS INC (FRX.CA) stock pay dividends?
FRX.CA does not pay a dividend.
When does FENNEC PHARMACEUTICALS INC (FRX.CA) report earnings?
FENNEC PHARMACEUTICALS INC (FRX.CA) will report earnings on 2025-03-17, after the market close.
What is the Price/Earnings (PE) ratio of FENNEC PHARMACEUTICALS INC (FRX.CA)?
FENNEC PHARMACEUTICALS INC (FRX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.06).
FRX.CA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to FRX.CA. When comparing the yearly performance of all stocks, FRX.CA is a bad performer in the overall market: 67.12% of all stocks are doing better.
FRX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to FRX.CA. While FRX.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
FRX.CA Financial Highlights
Over the last trailing twelve months FRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS increased by 94.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.92% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FRX.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to FRX.CA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 137.46% and a revenue growth 179.16% for FRX.CA